Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Affimed Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Affimed's earnings are forecast to decline at 10.6% per annum while its annual revenue is expected to grow at 59.1% per year. EPS is expected to grow by 19.5% per annum.

Anahtar bilgiler

-10.6%

Kazanç büyüme oranı

19.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.6%
Gelir büyüme oranı	59.1%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	01 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts

Sep 04

Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better

Jun 11

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

Aug 15

Need To Know: Analysts Just Made A Substantial Cut To Their Affimed N.V. (NASDAQ:AFMD) Estimates

Apr 20

Announcing: Affimed (NASDAQ:AFMD) Stock Increased An Energizing 177% In The Last Three Years

Feb 15

Affimed and Roche collaborate to study AFM24 in solid tumors

Feb 03

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:AFMD - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	13	-100	137	-120	5
12/31/2025	6	-81	65	-104	6
12/31/2024	3	-64	15	-60	6
6/30/2024	7	-79	-88	-84	N/A
3/31/2024	9	-93	-105	-101	N/A
12/31/2023	14	-106	-114	-110	N/A
9/30/2023	21	-119	-119	-116	N/A
6/30/2023	34	-111	-117	-117	N/A
3/31/2023	39	-101	-110	-110	N/A
12/31/2022	43	-86	-106	-105	N/A
9/30/2022	42	-76	-104	-102	N/A
6/30/2022	36	-76	-111	-108	N/A
3/31/2022	38	-76	-102	-99	N/A
12/31/2021	42	-58	-90	-87	N/A
9/30/2021	41	-49	-45	-43	N/A
6/30/2021	43	-38	-23	-21	N/A
3/31/2021	36	-32	-20	-19	N/A
12/31/2020	29	-41	-20	-19	N/A
9/30/2020	22	-39	-34	-34	N/A
6/30/2020	14	-44	-42	-42	N/A
3/31/2020	15	-43	-34	-32	N/A
12/31/2019	21	-32	-31	-29	N/A
9/30/2019	41	-11	42	44	N/A
6/30/2019	39	-12	44	46	N/A
3/31/2019	35	-9	42	43	N/A
12/31/2018	24	-19	49	49	N/A
9/30/2018	2	-35	-30	-30	N/A
6/30/2018	2	-31	-28	-28	N/A
3/31/2018	2	-31	N/A	-25	N/A
12/31/2017	2	-30	N/A	-26	N/A
9/30/2017	3	-29	N/A	-27	N/A
6/30/2017	3	-31	N/A	-28	N/A
3/31/2017	5	-32	N/A	-31	N/A
12/31/2016	6	-32	N/A	-32	N/A
9/30/2016	7	-33	N/A	-30	N/A
6/30/2016	7	-30	N/A	-28	N/A
3/31/2016	7	-27	N/A	-23	N/A
12/31/2015	8	-20	N/A	-19	N/A
9/30/2015	7	-19	N/A	-20	N/A
6/30/2015	7	-5	N/A	-15	N/A
3/31/2015	6	14	N/A	-15	N/A
12/31/2014	4	0	N/A	-11	N/A
9/30/2014	8	2	N/A	-7	N/A
6/30/2014	7	-16	N/A	-3	N/A
3/31/2014	6	-38	N/A	-3	N/A
12/31/2013	6	-26	N/A	-6	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AFMD is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: AFMD is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: AFMD is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: AFMD's revenue (59.1% per year) is forecast to grow faster than the US market (8.7% per year).

Yüksek Büyüme Geliri: AFMD's revenue (59.1% per year) is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if AFMD's Return on Equity is forecast to be high in 3 years time

Affimed Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates fall by 14%

Consensus revenue estimates decrease by 22%

Consensus revenue estimates increase by 28%

Consensus forecasts updated

Consensus revenue estimates fall by 23%

Consensus EPS estimates increase to -€0.25

Recent updates

Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts

Affimed N.V. Announces Chief Executive Officer Changes

Affimed N.V. to Report Q2, 2024 Results on Sep 05, 2024

Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better

Affimed N.V. to Report Q1, 2024 Results on Jun 12, 2024

Affimed N.V., Annual General Meeting, Jun 26, 2024

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

Affimed N.V. to Report Fiscal Year 2023 Results on Mar 28, 2024

Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer

Affimed N.V. Announces CEO Changes

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic Nk in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (Bv) and Checkpoint Inhibitors (Cpis)

Affimed N.V. Announces Executive Changes

Affimed N.V. to Report Q3, 2023 Results on Nov 14, 2023

Affimed N.V. Presents Preclinical Data Showing That Addition of an Innate Cell Engager to Nk and Car-Nk Cells

Affimed N.V. Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

Affimed Announces Listing Transfer to Nasdaq Capital Markets

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK(R) for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Affimed N.V. Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 14%

Affimed N.V. to Report Q2, 2023 Results on Aug 10, 2023

Affimed N.V.(NasdaqGM:AFMD) dropped from Russell 2000 Dynamic Index

New minor risk - Market cap size

Affimed Announces Addition of Constanze Ulmer-Eilfort to Its Supervisory Board

Consensus revenue estimates decrease by 22%

Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Affimed N.V., Annual General Meeting, Jun 21, 2023

Affimed N.V. to Report Q1, 2023 Results on May 23, 2023

Affimed N.V. Announces Abstracts at Annual Meeting of European Hematology Association

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Affimed N.V. Provides Regulatory Update for AFM13

Affimed N.V. Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

Affimed N.V. Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells

Consensus revenue estimates increase by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Affimed N.V. to Report Q3, 2022 Results on Nov 15, 2022

Affimed N.V. Announces Presentation of Phase 1/2 Data from Afm13 in Combination with Allogeneic NK Cells and Preclinical Afm28 Data At Ash 2022 Annual Meeting

Affimed downgraded to hold at Stifel as pipeline lacks development clarity

Health Check: How Prudently Does Affimed (NASDAQ:AFMD) Use Debt?

Now 26% undervalued after recent price drop

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Affimed Q2 2022 Earnings Preview

Affimed N.V. to Report Q2, 2022 Results on Aug 11, 2022

Affimed N.V. Establishes Scientific Advisory Board

Affimed: Preparing For Key Inflection Points

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Affimed N.V. Announces Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies At the Annual Meeting of the American Society of Clinical Oncology

Affimed N.V. to Report Q1, 2022 Results on Jun 01, 2022

Affimed N.V. Presents Data on Innate Cell Engagers Afm24 and Afm28 at 19th Meeting of the Society for Natural Immunity

Affimed N.V. Announces Data from the Dose Escalation Phase of the Phase 1/2A Study with the company’s Innate Cell Engager

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

Affimed N.V. Presents Findings from the Dose-Escalation Phase of the First-In-Human Study of AFM24 in Patients with EGFR-Positive Solid Tumors

Affimed Stock: 3 Points For The Bulls

Consensus revenue estimates fall by 23%

Affimed N.V. (NASDAQ:AFMD) Analysts Just Cut Their EPS Forecasts Substantially

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Affimed N.V. Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers After Freezing & Thawing

Affimed N.V. Announces Completion of Enrollment in Redirect, the Registration-Directed Study of Afm13 in PTCL

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed N.V. to Discuss Treatment of Cd30-Positive Lymphoma Patients with Cord Blood-Derived Natural Killer Cells Pre-Complexed with Innate Cell Engager AFM13

Affimed N.V. Initiates Patient Recruitment for A Phase 1/2A Trial of Innate Cell Engager Afm24 in Combination with Roche’S Anti-Pd-L1 Checkpoint Inhibitor Atezolizumab

Affimed Announces Interim Clinical Results from the Investigator-Initiated Phase 1-2 Study At the University of Texas MD Anderson Cancer Center

Third quarter 2021 earnings released: €0.14 loss per share (vs €0.069 loss in 3Q 2020)